Summary I chose to summarize an article on a new antifungal called eberconazole. Twenty to twenty-five percent of the world's population is affected by dermatophyte infection. This is a parasitic skin infection caused by a fungus. The most common fungal species responsible for dermatophytosis are Trichophyton, Epidermophyton and Microsporum. It is caused by parasitic organisms that attach to the keratin of the skin. They feed on keratin and form colonies. These infections are limited to the surface layers of the skin, so topical antifungal agents are an excellent treatment. Although oral and topical antifungals can be used, topical treatments are the first-line medications for localized dermatophytosis due to a decreased number of adverse effects, increased effectiveness and treatment focus, shorter treatment period required, ease of use and application. reduction in treatment duration and increase in compliance. There are many antifungals on the market and choosing the best drug for treatment is made more difficult due to problems in diagnosing the infection, signs and symptoms that are not the norm for clinical presentation, prevalence drug-resistant strains, the growing population of immunocompromised people and poor treatment compliance. Eberconazole is a derivative of imidazole initially launched on the market in Spain in 2005 by Salvat laboratories and which is now marketed in many countries. This article reviews the pharmacology of this drug, its clinical use, and its effectiveness. The molecular structure of eberconazole is C18H14Cl2N2. It is a broad-spectrum antifungal that has been shown to be effective in combating dermatophytosis, candidiasis, and other yeast infections, including Malassezia furfur... middle of article..... .eberconazole in addition to this article and it seems to be a promising product. medicine for the future. This makes me want to continue monitoring its emergence in the United States. It is currently used in many countries other than the United States. It is possible to encounter patients who use this medication because they obtained it elsewhere. The more we know about drugs being studied or available in other countries, the more we will be able to better treat patients who may use these drugs. I will continue to monitor that this medication is available in the United States so that I may one day use it in my practice. Kumar, N., Bellary, S., ...Rao, P.K. (2012). Eberconazole-Pharmacological and clinical review. Indian Journal of Dermatology, Venereology and Leprology, 78(2), 217-222.